On this page
Two clinics can both offer “stem cell therapy” and be selling genuinely different products. Autologous versus allogeneic — your own cells or a donor’s — changes the procedure you undergo, the cells you receive, the time it takes, the price and the evidence that applies.
The two options
Autologous cells come from you. Fat is collected by a small liposuction, or marrow is aspirated from the pelvis, usually under local anaesthetic with sedation.
Allogeneic cells come from a donor. In practice this almost always means umbilical cord tissue donated after a normal delivery, with maternal consent and screening.
Both are then typically expanded in culture before use, because a raw harvest rarely contains enough cells for a therapeutic dose.
Neither is simply better. They trade different things against each other, and which trade suits you depends on your age, your condition and how quickly you need treatment.
The case for your own cells
No donor. No question of immune recognition, and no dependence on someone else’s screening having been done properly.
It is the older approach, and some of the longer-standing trial evidence uses it — a phase III knee trial used autologous adipose-derived cells — Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells — as did other randomised work — Intra-Articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells and Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees.
In multiple sclerosis, the autologous approach has been studied for both procedures — Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive MS.
It also sidesteps a regulatory question in some jurisdictions, where minimally manipulated autologous tissue is treated differently from a donor product.
The case against your own cells
Cell number and quality fall with age, and with several chronic conditions. A seventy-year-old with diabetes is not donating the same starting material as a thirty-year-old athlete.
The harvest is a second procedure. It carries donor-site risks, takes time, and for marrow aspiration is genuinely uncomfortable.
It also takes weeks. Tissue must be collected, cells isolated and then expanded, which for a travelling patient means either two trips or a long stay — see the international patients page.
And it makes blinding almost impossible in trials, because a patient who has had a liposuction knows which arm they are in.
The case for donor cells
Cord-derived cells are young, uniform and available without any harvest procedure. For a patient flying in, that removes the largest scheduling obstacle.
Batches can be characterised in advance, which makes dose and quality more consistent than a preparation grown from whichever tissue a particular patient provided.
There is randomised evidence using cord-derived cells, including the knee dosing trial — Umbilical Cord-Derived Mesenchymal Stromal Cells for Knee Osteoarthritis — a diabetic foot ulcer trial — A Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcer — and a systematic review across autoimmune disease — mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases.
The case against donor cells
Everything rests on donor screening and processing you cannot inspect. Infectious disease screening, maternal history and sterility testing all happen before you are involved.
MSCs are often described as immune-privileged. That is a simplification — immune responses to allogeneic MSCs are described in the literature, and repeat dosing raises the question more sharply than a single dose does.
Regulatory treatment is also stricter in many jurisdictions, because a donor product is unambiguously a manufactured biological rather than a patient’s own tissue returned to them.
A systematic review of controlled studies using cord blood for regenerative therapy identified barriers in assessing exactly this kind of evidence — Systematic review of controlled clinical studies using umbilical cord blood for regenerative therapy.
A distinction inside the donor category
Umbilical cord blood and umbilical cord tissue are not the same thing, and both get called “cord stem cells”.
Cord blood is rich in haematopoietic cells. Cord tissue is where mesenchymal stromal cells come from. They have different biology and different evidence.
A 2026 meta-analysis in cerebral palsy found it necessary to explicitly separate the two — distinguishing cord blood infusions from mesenchymal stromal cells — which tells you how often they had been pooled.
See HSCT versus MSC infusion for the same problem in a different guise.
Which head-to-head evidence exists
Very little directly. The 2024 network meta-analysis in knee osteoarthritis is the closest thing, comparing cell types indirectly through their trials — Transplantation of three mesenchymal stem cells for knee osteoarthritis, which cell and type are more beneficial?.
It found differences, which is the useful finding. Anyone telling you the source does not matter is going beyond what that analysis supports.
Indirect comparison is weaker than a trial randomising patients between the two, and no such trial is widely available.
That gap is unlikely to close soon, because such a trial would be expensive and no commercial party benefits from the result. It is worth knowing which questions the literature is structurally unlikely to answer.
How to use this when choosing
If you are older or have a chronic condition affecting your tissue, ask what yield is expected from your own harvest and what happens if it is low.
If you are being offered donor cells, ask where they came from, what donor screening was done, and what release testing the batch passed.
If a clinic offers only one type, ask why — the honest answer is sometimes logistics rather than clinical reasoning, and that is fine if it is said.
See autologous therapy and cord-derived therapy.
Frequently asked questions
Which is better?
Neither in general. Autologous avoids donor questions; allogeneic avoids a harvest and gives more consistent batches. The right answer depends on your age, condition and schedule.
Do my own cells get worse with age?
Yield and quality generally decline with age and with several chronic conditions, which is a real argument for donor cells in older patients.
Will donor cells be rejected?
MSCs are often called immune-privileged, which is a simplification. Immune responses are described in the literature, particularly with repeat dosing.
Is cord blood the same as cord tissue?
No. Cord blood is rich in blood-forming cells; cord tissue is the mesenchymal source. A 2026 meta-analysis had to separate them explicitly because they were being pooled.
How much longer does autologous take?
Weeks, because tissue must be collected then expanded. For a travelling patient that usually means two trips or a long stay.
Has anyone compared them directly?
Not in a widely available randomised trial. The 2024 network meta-analysis compares them indirectly and did find differences between cell types.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.